{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,15]],"date-time":"2026-02-15T15:10:30Z","timestamp":1771168230819,"version":"3.50.1"},"reference-count":40,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T00:00:00Z","timestamp":1698192000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pancreatology"],"published-print":{"date-parts":[[2023,12]]},"DOI":"10.1016\/j.pan.2023.10.017","type":"journal-article","created":{"date-parts":[[2023,10,25]],"date-time":"2023-10-25T08:55:40Z","timestamp":1698224140000},"page":"964-969","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["Clinical features of germline BRCA1\/2 or ATM pathogenic variant positive pancreatic cancer in Japan"],"prefix":"10.1016","volume":"23","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6278-1450","authenticated-orcid":false,"given":"Hidetoshi","family":"Kitamura","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6560-7503","authenticated-orcid":false,"given":"Chigusa","family":"Morizane","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8240-007X","authenticated-orcid":false,"given":"Noriko","family":"Tanabe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ikeda","family":"Go","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuta","family":"Maruki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9153-3798","authenticated-orcid":false,"given":"Akihiro","family":"Ohba","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshikuni","family":"Nagashio","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shunsuke","family":"Kondo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0394-6876","authenticated-orcid":false,"given":"Susumu","family":"Hijioka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hideki","family":"Ueno","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1607-3899","authenticated-orcid":false,"given":"Teruhiko","family":"Yoshida","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1729-807X","authenticated-orcid":false,"given":"Takuji","family":"Okusaka","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pan.2023.10.017_bib1","first-page":"7","article-title":"Cancer statistics","volume":"69","author":"Siegel","year":"2019","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.pan.2023.10.017_bib2","doi-asserted-by":"crossref","first-page":"1944","DOI":"10.1158\/1078-0432.CCR-14-2600","article-title":"Very long-term survival following resection for pancreatic cancer is not explained by commonly mutated genes: results of whole-exome sequencing analysis","volume":"21","author":"Dal Molin","year":"2015","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib3","doi-asserted-by":"crossref","first-page":"1817","DOI":"10.1056\/NEJMoa1011923","article-title":"FOLFIRINOX versus gemcitabine for metastatic pancreatic cancer","volume":"364","author":"Conroy","year":"2011","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2023.10.017_bib4","doi-asserted-by":"crossref","first-page":"6747","DOI":"10.1038\/srep06747","article-title":"Survival improvement in patients with pancreatic cancer by decade: a period analysis of the SEER database, 1981-2010","volume":"4","author":"Sun","year":"2014","journal-title":"Sci Rep"},{"key":"10.1016\/j.pan.2023.10.017_bib5","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1056\/NEJMoa1304369","article-title":"Increased survival in pancreatic cancer with nab-paclitaxel plus gemcitabine","volume":"369","author":"Von Hoff","year":"2013","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2023.10.017_bib6","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1016\/j.bpg.2009.02.001","article-title":"Hereditary pancreatic cancer: a clinical perspective","volume":"23","author":"Greer","year":"2009","journal-title":"Best Pract Res Clin Gastroenterol"},{"key":"10.1016\/j.pan.2023.10.017_bib7","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1158\/2159-8290.CD-15-0402","article-title":"Whole genome sequencing defines the genetic heterogeneity of familial pancreatic cancer","volume":"6","author":"Roberts","year":"2016","journal-title":"Cancer Discov"},{"key":"10.1016\/j.pan.2023.10.017_bib8","doi-asserted-by":"crossref","first-page":"11182","DOI":"10.3748\/wjg.v20.i32.11182","article-title":"Pancreatic ductal adenocarcinoma: risk factors, screening, and early detection","volume":"20","author":"Becker","year":"2014","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pan.2023.10.017_bib9","doi-asserted-by":"crossref","first-page":"3124","DOI":"10.1200\/JCO.2014.59.7401","article-title":"Germline BRCA mutations in a large clinic-based cohort of patients with pancreatic adenocarcinoma","volume":"33","author":"Holter","year":"2015","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib10","first-page":"3789","article-title":"Evaluation of candidate genes MAP2K4, MADH4, ACVR1B, and BRCA2 in familial pancreatic cancer: deleterious BRCA2 mutations in 17","volume":"62","author":"Murphy","year":"2002","journal-title":"Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib11","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.1093\/jnci\/djy024","article-title":"Prospective evaluation of germline alterations in patients with exocrine pancreatic neoplasms","volume":"110","author":"Lowery","year":"2018","journal-title":"J\u00a0Natl Cancer Inst"},{"key":"10.1016\/j.pan.2023.10.017_bib12","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1002\/cncr.29664","article-title":"Identification of germline genetic mutations in patients with pancreatic cancer","volume":"121","author":"Salo-Mullen","year":"2015","journal-title":"Cancer"},{"key":"10.1016\/j.pan.2023.10.017_bib13","doi-asserted-by":"crossref","first-page":"2005","DOI":"10.1038\/bjc.2012.483","article-title":"The incidence of pancreatic cancer in BRCA1 and BRCA2 mutation carriers","volume":"107","author":"Iqbal","year":"2012","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2023.10.017_bib14","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1001\/jamaoncol.2022.0476","article-title":"Expansion of cancer risk profile for BRCA1 and BRCA2 pathogenic variants","volume":"8","author":"Momozawa","year":"2022","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib15","doi-asserted-by":"crossref","first-page":"2401","DOI":"10.1001\/jama.2018.6228","article-title":"Association between inherited germline mutations in cancer predisposition genes and risk of pancreatic cancer","volume":"319","author":"Hu","year":"2018","journal-title":"JAMA"},{"key":"10.1016\/j.pan.2023.10.017_bib16","article-title":"PARP inhibitors as a therapeutic agent for homologous recombination deficiency in breast cancers","volume":"8","author":"Keung","year":"2019","journal-title":"J\u00a0Clin Med"},{"key":"10.1016\/j.pan.2023.10.017_bib17","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1056\/NEJMoa1903387","article-title":"Maintenance olaparib for germline BRCA-mutated metastatic pancreatic cancer","volume":"381","author":"Golan","year":"2019","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.pan.2023.10.017_bib18","doi-asserted-by":"crossref","first-page":"1378","DOI":"10.1200\/JCO.19.02931","article-title":"Randomized, multicenter, phase II trial of gemcitabine and cisplatin with or without veliparib in patients with pancreas adenocarcinoma and a germline BRCA\/PALB2 mutation","volume":"38","author":"O'Reilly","year":"2020","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib19","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1200\/JCO.21.00003","article-title":"Phase II study of maintenance rucaparib in patients with platinum-sensitive advanced pancreatic cancer and a pathogenic germline or somatic variant in BRCA1, BRCA2, or PALB2","volume":"39","author":"Reiss","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib20","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1053\/j.gastro.2004.05.003","article-title":"Genetic testing and phenotype in a large kindred with attenuated familial adenomatous polyposis","volume":"127","author":"Burt","year":"2004","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2023.10.017_bib21","doi-asserted-by":"crossref","first-page":"556","DOI":"10.1053\/j.gastro.2014.11.042","article-title":"Prevalence of germline mutations in cancer predisposition genes in patients with pancreatic cancer","volume":"148","author":"Grant","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2023.10.017_bib22","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1200\/JCO.20.03238","article-title":"Homologous recombination deficiency in pancreatic cancer: a systematic review and prevalence meta-analysis","volume":"39","author":"Casolino","year":"2021","journal-title":"J\u00a0Clin Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib23","doi-asserted-by":"crossref","first-page":"1664","DOI":"10.1001\/jamaoncol.2021.3701","article-title":"Risk of pancreatic cancer among individuals with pathogenic variants in the ATM gene","volume":"7","author":"Hsu","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/0016-5085(93)90368-M","article-title":"Genetics, natural history, tumor spectrum, and pathology of hereditary nonpolyposis colorectal cancer: an updated review","volume":"104","author":"Lynch","year":"1993","journal-title":"Gastroenterology"},{"key":"10.1016\/j.pan.2023.10.017_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.ctrv.2019.101895","article-title":"Should platinum-based chemotherapy be preferred for germline BReast CAncer genes (BRCA) 1 and 2-mutated pancreatic ductal adenocarcinoma (PDAC) patients? A systematic review and meta-analysis","volume":"80","author":"Rebelatto","year":"2019","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.pan.2023.10.017_bib26","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1002\/ags3.12482","article-title":"Germline DNA damage repair gene mutations in pancreatic cancer patients with personal\/family histories of pancreas\/breast\/ovarian\/prostate cancer in a Japanese population","volume":"5","author":"Hata","year":"2021","journal-title":"Ann Gastroenterol Surg"},{"key":"10.1016\/j.pan.2023.10.017_bib27","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s10038-022-01097-y","article-title":"Genetic medicine in companion diagnostics of germline BRCA testing of Japanese pancreatic cancer patients","volume":"68","author":"Matsubayashi","year":"2023","journal-title":"J\u00a0Hum Genet"},{"key":"10.1016\/j.pan.2023.10.017_bib28","doi-asserted-by":"crossref","first-page":"5018","DOI":"10.1158\/1078-0432.CCR-18-0531","article-title":"Molecular profiling of patients with pancreatic cancer: initial results from the know your tumor initiative","volume":"24","author":"Pishvaian","year":"2018","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib29","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/gim.2014.151","article-title":"ACMG policy statement: updated recommendations regarding analysis and reporting of secondary findings in clinical genome-scale sequencing","volume":"17","year":"2015","journal-title":"Genet Med"},{"key":"10.1016\/j.pan.2023.10.017_bib30","doi-asserted-by":"crossref","first-page":"1374","DOI":"10.1002\/cncr.31218","article-title":"Phase 1 trial evaluating cisplatin, gemcitabine, and veliparib in 2 patient cohorts: germline BRCA mutation carriers and wild-type BRCA pancreatic ductal adenocarcinoma","volume":"124","author":"O'Reilly","year":"2018","journal-title":"Cancer"},{"key":"10.1016\/j.pan.2023.10.017_bib31","doi-asserted-by":"crossref","first-page":"439","DOI":"10.6004\/jnccn.2021.0017","article-title":"Pancreatic adenocarcinoma, version 2.2021, NCCN clinical practice guidelines in Oncology","volume":"19","author":"Tempero","year":"2021","journal-title":"J\u00a0Natl Compr Cancer Netw"},{"key":"10.1016\/j.pan.2023.10.017_bib32","doi-asserted-by":"crossref","first-page":"6505","DOI":"10.1158\/1078-0432.CCR-20-1788","article-title":"Effect of germline mutations in homologous recombination repair genes on overall survival of patients with pancreatic adenocarcinoma","volume":"26","author":"Yadav","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib33","article-title":"Prevalence of homologous recombination-related gene mutations across multiple cancer types","volume":"2018","author":"Heeke","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib34","doi-asserted-by":"crossref","first-page":"1132","DOI":"10.1038\/bjc.2014.418","article-title":"Overall survival and clinical characteristics of pancreatic cancer in BRCA mutation carriers","volume":"111","author":"Golan","year":"2014","journal-title":"Br J Cancer"},{"key":"10.1016\/j.pan.2023.10.017_bib35","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1200\/PO.19.00346","article-title":"Platinum-based chemotherapy in metastatic prostate cancer with DNA repair gene alterations","volume":"4","author":"Mota","year":"2020","journal-title":"JCO Precis Oncol"},{"key":"10.1016\/j.pan.2023.10.017_bib36","doi-asserted-by":"crossref","first-page":"3239","DOI":"10.1158\/1078-0432.CCR-20-0418","article-title":"Genomic methods identify homologous recombination deficiency in pancreas adenocarcinoma and optimize treatment selection","volume":"26","author":"Park","year":"2020","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib37","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1097\/MPA.0000000000000447","article-title":"Clinicopathological features of 15 occult and 178 clinical pancreatic ductal adenocarcinomas in 8339 autopsied elderly patients","volume":"45","author":"Matsuda","year":"2016","journal-title":"Pancreas"},{"key":"10.1016\/j.pan.2023.10.017_bib38","doi-asserted-by":"crossref","first-page":"4782","DOI":"10.1158\/1078-0432.CCR-22-1483","article-title":"Clinico-genomic characterization of ATM and HRD in pancreas cancer: application for practice","volume":"28","author":"Park","year":"2022","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.pan.2023.10.017_bib39","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1038\/s41379-019-0317-6","article-title":"Histomorphology of pancreatic cancer in patients with inherited ATM serine\/threonine kinase pathogenic variants","volume":"32","author":"Hutchings","year":"2019","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pan.2023.10.017_bib40","doi-asserted-by":"crossref","first-page":"455","DOI":"10.1002\/path.6136","article-title":"Somatic loss of ATM is a late event in pancreatic tumorigenesis","volume":"260","author":"Paranal","year":"2023","journal-title":"J\u00a0Pathol"}],"container-title":["Pancreatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032301829X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S142439032301829X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,25]],"date-time":"2025-10-25T16:21:00Z","timestamp":1761409260000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S142439032301829X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12]]},"references-count":40,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2023,12]]}},"alternative-id":["S142439032301829X"],"URL":"https:\/\/doi.org\/10.1016\/j.pan.2023.10.017","relation":{},"ISSN":["1424-3903"],"issn-type":[{"value":"1424-3903","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical features of germline BRCA1\/2 or ATM pathogenic variant positive pancreatic cancer in Japan","name":"articletitle","label":"Article Title"},{"value":"Pancreatology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pan.2023.10.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of IAP and EPC.","name":"copyright","label":"Copyright"}]}}